At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
Testerone Transdermal Systemdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men
In Brief
A Phase 1 clinical trial evaluating Testerone Transdermal System for Hypogonadism. Completed, enrolled 40 participants across 3 sites.
Detailed Summary
The study will evaluate the pharmacokinetics of testosterone transdermal systems at steady-state in hypogonadal men.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedApr 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedApr 15, 2010
Enrollment StartApr 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.2 years ago
Interventions
Testerone Transdermal Systemdrug
Transdermal testosterone applied daily for 4 weeks